Cargando…

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

KRAS mutant colorectal cancer (CRC) patients develop lung and brain metastases more frequently than KRAS wild‐type (WT) counterpart. We retrospectively investigated the prognostic role of KRAS,BRAF, and PIK3CA (exon 20) mutations and loss of phosphatase and tensin homolog (PTEN) in surgically resect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghidini, Michele, Personeni, Nicola, Bozzarelli, Silvia, Baretti, Marina, Basso, Gianluca, Bianchi, Paolo, Tronconi, Maria Chiara, Pressiani, Tiziana, Grizzi, Fabio, Giordano, Laura, Malesci, Alberto, Alloisio, Marco, Laghi, Luigi, Santoro, Armando, Rimassa, Lorenza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735767/ https://www.ncbi.nlm.nih.gov/pubmed/26715198 http://dx.doi.org/10.1002/cam4.592

Ejemplares similares

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022)

Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
por: Personeni, Nicola, et al.
Publicado: (2022)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
por: Malesci, Alberto, et al.
Publicado: (2017)

Combined low-FOXP3+ and -CD3+tumor infiltrating lymphocytes: a signature of stage II MSS colorectal cancer at high-risk of recurrence
por: Di Caro, Giuseppe, et al.
Publicado: (2013)

Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients
por: Milana, Flavio, et al.
Publicado: (2022)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
por: Personeni, Nicola, et al.
Publicado: (2020)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

Iron Metabolism in Cancer Progression
por: Forciniti, Stefania, et al.
Publicado: (2020)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver
por: Di Gioia, Sonia, et al.
Publicado: (2006)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer
por: Cavalleri, Tommaso, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
por: Balsano, Rita, et al.
Publicado: (2023)

On the prognostic & predictive impact of immune cells system in colorectal cancer
por: Grizzi, Fabio, et al.
Publicado: (2012)

Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer
por: Laghi, Luigi, et al.
Publicado: (2020)

Prognostic Value of Colorectal Cancer Biomarkers
por: Bianchi, Paolo, et al.
Publicado: (2011)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Epithelial to Mesenchymal Transition: A Challenging Playground for Translational Research. Current Models and Focus on TWIST1 Relevance and Gastrointestinal Cancers
por: Greco, Luana, et al.
Publicado: (2021)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
por: Warren, Hannah R., et al.
Publicado: (2022)

Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia
por: Malesci, A, et al.
Publicado: (2014)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival
por: Wang, Danyang, et al.
Publicado: (2021)

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
por: Personeni, Nicola, et al.
Publicado: (2021)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study)
por: Comito, Tiziana, et al.
Publicado: (2023)

Arid1a restrains Kras-dependent changes in acinar cell identity
por: Livshits, Geulah, et al.
Publicado: (2018)

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis
por: Tronconi, Maria Chiara, et al.
Publicado: (2020)

Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients
por: Laghi, L, et al.
Publicado: (2001)

Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis
por: Celesti, G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rofok8qf4i010d5g1to5t7rrok